How many institutional investors hold NKTR?

4 tracked institutional investors disclosed a position in NKTR (NEKTAR THERAPEUTICS) in their most recent 13F filing.

Who is the largest institutional holder of NKTR?

Ken Griffin, Citadel Advisors, holds the largest disclosed position in NKTR, valued at $48M.

Did institutional ownership of NKTR increase or decrease?

Across recent 13F filings, tracked investors recorded 0 new positions, 0 increased, 0 reduced, and 0 fully exited NKTR.

Where does this NKTR ownership data come from?

SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.

NKTR — NEKTAR THERAPEUTICS

Name: NEKTAR THERAPEUTICS (NKTR) — Institutional Ownership
Creator: InvestorLens
License: https://www.sec.gov/about/website-policies

Public company

For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About NEKTAR THERAPEUTICS (NKTR)

NEKTAR THERAPEUTICS (NKTR) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $48M. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in NKTR

/100

Mixed Activity

Added / Increased0

Reduced0

Exited0

No recent activity recorded.

Crowded Trade Score™

How many top investors track NKTR

/100

Emerging Interest

4investors

A small number of top investors own this.

UndiscoveredCrowded

151015+

NKTR Ownership Composition

How NEKTAR THERAPEUTICS is held across tracked investor types, based on reported 13F positions.

Dominant Type

Other

99% of tracked value

Institutions

tracked investors

Total Reported

$79.7M

combined 13F value

Other98.8%
Hedge Funds1.2%

Other(3)

98.8%

Hedge Funds(1)

1.2%

Tracked investors reporting NKTR

Investor	Firm	Shares	Market value	% of portfolio	As of
Ken Griffin	Citadel Advisors	665.4K	$47.9M	0.01%	Mar 31, 2026
Izzy Englander	Millennium Management	404.3K	$29.1M	0.01%	Mar 31, 2026
Steve Cohen	Point72 Asset Management	13.4K	$961.5K	0.00%	Mar 31, 2026
Paul Tudor Jones	Tudor Investment Corp	24.8K	$1.8M	0.00%	Mar 31, 2026

Ken GriffinMar 31, 2026
Citadel Advisors
Shares
665.4K
Value
$47.9M
% Portfolio
0.01%
Izzy EnglanderMar 31, 2026
Millennium Management
Shares
404.3K
Value
$29.1M
% Portfolio
0.01%
Steve CohenMar 31, 2026
Point72 Asset Management
Shares
13.4K
Value
$961.5K
% Portfolio
0.00%
Paul Tudor JonesMar 31, 2026
Tudor Investment Corp
Shares
24.8K
Value
$1.8M
% Portfolio
0.00%

Recent activity

Investor	Action	Δ %	Current value	Filing date
No recent activity.

No recent activity.

Frequently asked questions

How many institutional investors hold NKTR?: 4 tracked institutional investors disclosed a position in NKTR (NEKTAR THERAPEUTICS) in their most recent 13F filing.
Who is the largest institutional holder of NKTR?: Ken Griffin, Citadel Advisors, holds the largest disclosed position in NKTR, valued at $48M.
Did institutional ownership of NKTR increase or decrease?: Across recent 13F filings, tracked investors recorded 0 new positions, 0 increased, 0 reduced, and 0 fully exited NKTR.
Where does this NKTR ownership data come from?: SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.